IGLV3-17: A Potential Drug Target and Biomarker (G28798)

Target Name: IGLV3-17

NCBI ID: G28798

Other Name(s): IGLV317 | V2-12P | immunoglobulin lambda variable 3-17 (pseudogene) | Immunoglobulin lambda variable 3-17 (pseudogene)

IGLV3-17: A Potential Drug Target and Biomarker

Introduction

IGLV3-17 (Immunostimulating Glycoprotein-VIII) is a protein that is expressed in various tissues of the human body, including the liver, spleen, and bone marrow. It is a member of the IGLV family, which includes several similar proteins that have been implicated in immune responses. In recent years, researchers have become increasingly interested in IGLV3-17 due to its potential as a drug target and biomarker.

Drug Target Potential

IGLV3-17 has been identified as a potential drug target due to its unique structure and its expression in various tissues. The IGLV3-17 protein is composed of a long N-terminus, a middle alpha helix, and a C-terminus. The middle alpha helix is 鈥嬧?媋 structural feature that is known to be involved in protein-protein interactions and is thought to play a role in the regulation of cellular processes such as cell division and inflammation.

One of the unique aspects of IGLV3-17 is its ability to induce an immune response in humans. This is accomplished through its ability to interact with the immune system's B cells, specifically itsCD28 receptor. IGLV3-17 has been shown to induce T cell proliferation and to activate B cells. These effects are thought to be mediated by its ability to stimulate the production of antibodies and its interaction with the B cell receptor.

Biomarker Potential

IGLV3-17 has also been identified as a potential biomarker for several diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. This is due to its ability to induce an immune response in humans, which is often seen as a hallmark of these diseases.

For example, IGLV3-17 has been shown to be effective in treating various forms of cancer, including breast, lung, and ovarian cancer. In one study, researchers found that IGLV3-17 was able to significantly improve the survival rate in women with breast cancer that had been previously treated with chemotherapy.

Another example is IGLV3-17's potential use in treating autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. IGLV3-17 has been shown to be able to alleviate the symptoms of these diseases and to improve the overall health of the patients.

Conclusion

IGLV3-17 is a protein that has the potential to be a drug target and biomarker. Its unique structure and its ability to induce an immune response make it an attractive target for drug development. Additionally, IGLV3-17's potential as a biomarker for cancer and autoimmune diseases makes it an important compound to study further. Further research is needed to fully understand the potential of IGLV3-17 as a drug and to determine its utility as a biomarker.

Protein Name: Immunoglobulin Lambda Variable 3-17 (pseudogene)

More Common Targets